FN2 Earnings Intelligence
UnitedHealth Group (UNH) earnings history
UnitedHealth Group Incorporated (UNH) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.
Earnings History
UnitedHealth Group Incorporated
UnitedHealth Group delivered a decisive Q2 2026 beat, with adjusted EPS of $6.38 exceeding consensus by 29%, alongside a $112B revenue print and a 55% rise in operating earnings. The company raised full-year EPS guidance to $19.50-$20, reflecting improving Medicare Advantage cost trends and accelerating AI-driven operational efficiencies. Commercial cost trends remain elevated above 11% and Medicaid margins stay constrained, but management's confident tone, expanded capital return ($5B buybacks, dividend hike to $9.28), and the closed Alegeus combination signal conviction in the forward trajectory.
UnitedHealth Group Incorporated
UnitedHealth delivered a clean beat in Q1 2026 - adjusted EPS of $7.23 (+11.9% vs consensus) on revenue of $112.0bn (+2.4% YoY) - with all four segments ahead of plan. The near-term story is margin recovery rather than membership volume: management is leaning on repricing, AI-enabled cost efficiencies (~$1.5bn AI investment targeting a 2:1 ROI), and digital engagement while guiding membership down about 1.3 million for the year. That balanced narrative - a beat today, deliberately shrinking volumes ahead, and FY2026 EPS reaffirmed above $18.25 - supports continued earnings growth, but it hinges on medical cost trends (MA trend ~7-8% vs ~10% pricing) staying contained and on regulators not moving the goalposts on Medicare Advantage rates or PBM rules.
UnitedHealth Group Incorporated
The quarter supports a constructive earnings-growth case, but the path depends on repricing, cost discipline and AI savings offsetting membership contraction, medical costs and regulatory pressure.
UnitedHealth Group Incorporated
The supplied analysis supports a cautiously constructive operating thesis: repricing, network optimization, Optum Rx demand and Optum Insight AI investments could support recovery, but membership pressure, medical costs, funding cuts and execution risks remain material.
UnitedHealth Group Incorporated
The call weakened the near-term earnings case: demand and Optum Rx growth remain constructive, but elevated care utilization and Optum Health reimbursement pressure led to lower guidance and raise execution risks.
Get the UNH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.